Kelsee, I am going to assume that “following” is the key word here but who knows maybe RVX will get lucky. 

Stonegate report; A quick google search shows Stonegate originally initiated coverage of RVX on Nov 5/15.  Looks like the writer spent some time on the RVX website and the latest RVX presentation - got the timeline slide with Q1 randomization of first US patients. Not sure, as the report states, that RVX will be in direct competition with LDL therapies (PCSK9’s they state). Perhaps when they talk about “delipitated” HDL programs they are referring to delipidated HDL programs (maybe they borrowed RVX’s proof reader eh GAC).  JMO but I would rather see the $7500/mo Stonegate is being paid for services spent on someone capable whose sole focus is going out and getting real analyst coverage for RVX.

What is it they say about doing the same dumba$$ stuff over and over and expecting a different result?